Management of Advanced Stage Hodgkin Lymphoma

Although advanced Hodgkin lymphoma is highly curable, balancing the high cure rate with long-term toxicity is challenging. ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine) is the standard chemotherapy regimen, producing a high cure rate with acceptable toxicity. Stanford V and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) are new regimens with encouraging results and are undergoing randomized clinical trials. The International Prognostic Score provides a clinical tool that may help identify patients with high-risk disease who may require a more aggressive regimen. Consolidative radiation's role in managing advanced Hodgkin lymphoma is still controversial, but it is most accepted for bulky or residual disease or after brief chemotherapy. The development and integration of newer imaging tools, such as fluorodeoxyglucose–positron emission tomography imaging, may allow a more precise evaluation of disease and help define which patients might benefit from consolidative treatment.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Ranjana Advani, MD, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305. E-mail: radvani@stanford.edu

References

  • 1.

    LongoDYoungRWesleyM. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol1986;4:12951306.

  • 2.

    DeVitaVTJrSimonRMHubbardSM. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med1980;92:587595.

    • Search Google Scholar
    • Export Citation
  • 3.

    VoseJBiermanPAndersonJ. CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity. J Clin Oncol1991;9:14211425.

    • Search Google Scholar
    • Export Citation
  • 4.

    HardingMJMcNultyLJPaulJ. Mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) for advanced Hodgkin's disease. Eur J Cancer1991;27:10021006.

    • Search Google Scholar
    • Export Citation
  • 5.

    HancockBWVaughan HudsonGVaughan HudsonB. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease—long term results. Br J Cancer1991;63:579582.

    • Search Google Scholar
    • Export Citation
  • 6.

    BonadonnaGZucaliRMonfardiniS. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer1975;36:252259.

    • Search Google Scholar
    • Export Citation
  • 7.

    CanellosGPAndersonJRPropertKJ. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med1992;327:14781484.

    • Search Google Scholar
    • Export Citation
  • 8.

    CanellosGPNiedzwieckiD. Long-term follow-up of Hodgkin's disease trial. N Engl J Med2002;346:14171418.

  • 9.

    VivianiSBonadonnaGSantoroA. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol1996;14:14211430.

    • Search Google Scholar
    • Export Citation
  • 10.

    GlickJHYoungMLHarringtonD. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol1998;16:1926.

    • Search Google Scholar
    • Export Citation
  • 11.

    DugganDBPetroniGRJohnsonJL. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol2003;21:607614.

    • Search Google Scholar
    • Export Citation
  • 12.

    VivianiSSantoroARagniG. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol1985;21:601605.

    • Search Google Scholar
    • Export Citation
  • 13.

    HasencleverDDiehlV. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med1998;339:15061514.

    • Search Google Scholar
    • Export Citation
  • 14.

    HorningSJHoppeRTBreslinS. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol2002;20:630637.

    • Search Google Scholar
    • Export Citation
  • 15.

    HorningSJHoppeRAdvaniR. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: mature data in early and advanced stage patients [abstract]. Blood2004;104Abstract 308.

    • Search Google Scholar
    • Export Citation
  • 16.

    YahalomJEdwards-BennetSJacobsJ. Stanford V and radiotherapy for advanced and locally extensive Hodgkin's disease (HD): the Memorial Sloan-Kettering Cancer Center (MSKCC) experience [abstract]. Blood2003Abstract 1459.

    • Search Google Scholar
    • Export Citation
  • 17.

    HorningSJWilliamsJBartlettNL. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol2000;18:972980.

    • Search Google Scholar
    • Export Citation
  • 18.

    AversaSMSalvagnoLSoraruM. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematol2004;112:141147.

    • Search Google Scholar
    • Export Citation
  • 19.

    JohnsonPHoskinPHorwichA. Stanford V (SV) regimen versus ABVD for the treatment of advanced Hodgkin lymphoma (HL): results of a UK NCRI/LTO randomised phase II trial [abstract]. Blood2004;104Abstract 311.

    • Search Google Scholar
    • Export Citation
  • 20.

    GobbiPGLevisAChisesiT. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol2005;23:91989207.

    • Search Google Scholar
    • Export Citation
  • 21.

    HasencleverDLoefflerMDiehlV. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol1996;7[suppl 4]:9598.

    • Search Google Scholar
    • Export Citation
  • 22.

    DiehlVFranklinJPfreundschuhM. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med2003;348:23862395.

    • Search Google Scholar
    • Export Citation
  • 23.

    ConnorsJM: State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol2005;23:64006408.

  • 24.

    DiehlVBrillantCFranklinJ. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12-trials of the German Hodgkin Study Group (GHSG) [abstract]. Blood2004;104Abstract 307.

    • Search Google Scholar
    • Export Citation
  • 25.

    SieberMBredenfeldHJostingA. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol2003;21:17341739.

    • Search Google Scholar
    • Export Citation
  • 26.

    MarkovaJZidkaMKozakT. Osteonecrosis as a complication of treating Hodgkin's lymphoma after BEACOPP chemotherapy. Ann Oncol2005;16(Suppl 5). Abstract 269.

    • Search Google Scholar
    • Export Citation
  • 27.

    FedericoMBelleiMBriceP. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol2003;21:23202325.

    • Search Google Scholar
    • Export Citation
  • 28.

    ProctorSJMackieMDawsonA. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer2002;38:795806.

    • Search Google Scholar
    • Export Citation
  • 29.

    YoungRCCanellosGPChabnerBA. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer1978;42:10011007.

    • Search Google Scholar
    • Export Citation
  • 30.

    LoefflerMBrosteanuOHasencleverD. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol1998;16:818829.

    • Search Google Scholar
    • Export Citation
  • 31.

    FermeCSebbanCHennequinC. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood2000;95:22462252.

    • Search Google Scholar
    • Export Citation
  • 32.

    HancockSLHoppeRTHorningSJ. Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med1988;109:183189.

    • Search Google Scholar
    • Export Citation
  • 33.

    AlemanBMRaemaekersJMTirelliU. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med2003; 348:23962406.

  • 34.

    LaskarSGuptaTVimalS. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?J Clin Oncol2004;22:6268.

    • Search Google Scholar
    • Export Citation
  • 35.

    FriedbergJWFischmanANeubergD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma2004;45:8592.

    • Search Google Scholar
    • Export Citation
  • 36.

    WirthASeymourJFHicksRJ. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med2002;112:262268.

    • Search Google Scholar
    • Export Citation
  • 37.

    NaumannRBeuthien-BaumannBReissA. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer2004;90:620625.

    • Search Google Scholar
    • Export Citation
  • 38.

    SpaepenKStroobantsSDupontP. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?Br J Haematol2001;115:272278.

    • Search Google Scholar
    • Export Citation
  • 39.

    JerusalemGBeguinYFassotteMF. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol2003;14:123130.

    • Search Google Scholar
    • Export Citation
  • 40.

    WeihrauchMRReDScheidhauerK. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood2001;98:29302934.

    • Search Google Scholar
    • Export Citation

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 27 27 10
PDF Downloads 4 4 3
EPUB Downloads 0 0 0